

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

NCT06657144

Status	RECRUITING
Phase	Phase 1
Sponsor	Coherus Oncology, Inc.
Enrollment	154 participants

Plain Language Summary

This study is testing CHS-114 — a new experimental drug — combined with toripalimab (an immunotherapy) and/or other cancer treatments in patients with advanced solid tumors (cancers that have spread and have not responded to standard treatments).

****You may be eligible if...****

- You have advanced solid tumor cancer with at least one measurable tumor on imaging
- Any side effects from prior cancer treatments have resolved to mild or baseline levels
- You are in adequate overall health and your organ function meets study requirements
- You are willing to undergo biopsies and study procedures

****You may NOT be eligible if...****

- You have active, uncontrolled brain metastases
- You have serious autoimmune disease or are on high-dose immune-suppressing medications
- You have had certain prior immunotherapy treatments that conflict with this study
- You have serious heart, liver, or kidney problems

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (17)

- At least 1 measurable lesion based on RECIST v1.1 as determined by the Investigator.
- Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgement.
- Histologically or cytologically documented unresectable, locally advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma that is human epidermal growth factor receptor 2 (HER2) - negative and microsatellite stable (MSS)/proficient mismatch repair (pMMR).
- Progressed during or after first line systemic therapy that includes a platinum and fluoropyrimidine doublet with or without anti-programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1)-directed therapy (that is, in the second line setting).
- Consent to provide tumor tissue samples (baseline and on-treatment) is required for enrollment.

... and 12 more (see full listing online)

Exclusion (16)

- History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years.
- Symptomatic or untreated central nervous system metastases, including leptomeningeal metastases, requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids.
- Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.

<https://clinicaltrials.gov/study/NCT06657144>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

- Prior exposure to anti-C-C motif chemokine receptor 8 (CCR8) antibody.
- History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody (mAb) therapy or any excipient in the study treatment.

... and 11 more (see full listing online)

Locations (30 total)

The University of Arizona Cancer Center, Tucson, Arizona, United States

City of Hope, Duarte, California, United States

University of Colorado - Aurora Cancer Center, Aurora, Colorado, United States

... and 27 more locations